QTTB vs IMVT vs KO vs ARDX vs PRAX

For growth investors, Ardelyx, Inc.

(ARDX) is the stronger pick with 22. 1% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Q32 Bio Inc. (QTTB) offers the better valuation at 5. 2x trailing P/E, making it the more compelling value choice. Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Q32 Bio Inc.

(QTTB) is the cheapest at 5. 2x versus The Coca-Cola Company at 27. 2x.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -90. 5% for Q32 Bio Inc. (QTTB). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus QTTB's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Immunovant, Inc. 's 1. 66β — meaning IMVT is approximately -928% more volatile than KO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ardelyx, Inc.

(ARDX) is pulling ahead at 22. 1% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Q32 Bio Inc. grew EPS 136. 8% year-over-year, compared to -52. 9% for Ardelyx, Inc.. Over a 3-year CAGR, QTTB leads at 100. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Q32 Bio Inc.

(QTTB) is the more profitable company, earning 55. 5% net margin versus -15. 1% for Ardelyx, Inc. — meaning it keeps 55. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QTTB leads at 31. 5% versus -10. 1% for ARDX. At the gross margin level — before operating expenses — QTTB leads at 99. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ARDX: 198.

8% to $17. 00.

In this comparison, KO (2.

5% yield) pays a dividend. QTTB, IMVT, ARDX, PRAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Praxis Precision Medicines, Inc. (PRAX) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, PRAX: -36. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (QTTB (Healthcare) and IMVT (Healthcare) and KO (Consumer Defensive) and ARDX (Healthcare) and PRAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: QTTB is a small-cap deep-value stock; IMVT is a small-cap quality compounder stock; KO is a large-cap quality compounder stock; ARDX is a small-cap high-growth stock; PRAX is a small-cap quality compounder stock. KO pays a dividend while QTTB, IMVT, ARDX, PRAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.